Journal of INTERNATIONAL MEDICAL RESEARCH
Effect of mitotane in patients with ectopic adrenocorticotropic hormone syndrome caused by advanced pancreatic neuroendocrine tumors: a case series and review of the literature
Journal of International Medical Research 2024, Vol. 52(1) 1-11 C The Author(s) 2024 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/03000605231220867 journals.sagepub.com/home/imr Sage
Shaobo Hu1,2, Xianhua Wang1,2, Fei Su2, Qiong Zhou1,2, Zhaoqing Li3, Jie Luo4 and Huangying Tan2 D
Abstract
Ectopic adrenocorticotropic hormone syndrome (EAS) is a rare condition caused by pancreatic neuroendocrine tumors (p-NETs). The severe hypercortisolemia that characterizes EAS is asso- ciated with a poor prognosis and survival. Mitotane is the only adrenolytic drug approved by the Food and Drug Administration and is often used to treat adrenocortical carcinoma. Combination therapy with mitotane and other adrenal steroidogenesis inhibitors is common for patients with Cushing’s syndrome (CS). Here, we describe three patients who developed EAS secondary to the liver metastasis of p-NETs. All three rapidly developed hypercortisolemia but no typical features of CS. They underwent anti-tumor and mitotane therapy, which rapidly reduced their blood cortisol concentrations and ameliorated their symptoms. Their hypercortisolemia was controlled long term using a low dose of mitotane. The principal adverse effects were a slight loss of appetite and occasional dizziness, and there were no severe adverse effects. Importantly, even when the tumor progressed, the patients’ circulating cortisol concentrations remained within the normal range. In summary, the present case series suggests that mitotane could be used to treat
‘Graduate School, Beijing University of Chinese Medicine, Beijing, China
2Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China
3Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China
4Department of Pathology, China-Japan Friendship Hospital, Beijing, China
Corresponding author:
Huangying Tan, Department of Integrative Oncology, China-Japan Friendship Hospital, No. 2 Yinghuayuan East Street, Chaoyang District, Beijing 100029, China. Email: tanhuangying@zryhyy.com.cn
cc
+ $ BY NC
Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
hypercortisolemia in patients with EAS caused by advanced p-NETs, in the absence of significant adverse effects.
Keywords
Pancreatic neuroendocrine tumor, ectopic adrenocorticotropic hormone syndrome, hypercorti- solemia, mitotane, case series, liver metastasis
Date received: 13 September 2023; accepted: 23 November 2023
Introduction
Ectopic adrenocorticotropic hormone syn- drome (EAS) is a rare condition that accounts for 5% to 10% of cases of adreno- corticotropic hormone (ACTH)-dependent Cushing’s disease.1 Malignant neoplasms that secrete ACTH include bronchial carci- noid, small-cell lung carcinoma, thymic carcinoid, pancreatic neuroendocrine tumor (p-NET), and acinic cell carcinoma of the parotid or pancreas. Of these, bronchial car- cinoid is the most common cause of EAS and p-NET accounts for approximately 15% of cases.2,3 p-NET is characterized by an insidious onset and typically have already metastasized at the time of diagnosis. Advanced tumors secrete large amounts of ACTH, which causes severe acute hypercor- tisolemia. A high serum cortisol concentra- tion can cause a series of complications that significantly worsen the prognosis of patients.4 Although bilateral adrenalectomy is an effective treatment for this hypercorti- solemia and prolongs the life of patients, it is associated with numerous potential intrao- perative complications that increase the risk of surgical mortality.3 Therefore, the identification of effective pharmacological treatments for hypercortisolemia would be especially important. Here, we report three patients with advanced p-NETs and EAS, whose hypercortisolemia was rapidly con- trolled by the administration of mitotane alone, resulting in significant clinical improvements and longer survival.
We obtained the patients’ consent for treatment, and the written informed con- sent for the publication of their cases was obtained from the relatives of the patients. The reporting of this study conforms to the CARE guidelines.6
Case descriptions
Case 1
A man of approximately 40 years of age underwent abdominal surgery (distal pan- createctomy, splenectomy, partial hepatec- tomy, and right hemicolectomy) in April 2017 for the treatment of a pancreatic neo- plasm with multiple liver metastases. During the surgery, a mass measuring 5.1 cm × 4.6 cm was found in the tail of his pancreas. Pathologic examination revealed a grade 2 (G2) neuroendocrine tumor with a Ki-67 index of 3%. Following the surgery, the patient underwent anti-tumor therapy for several years, but throughout this period, he experienced repeated episodes of hypokalemia and hyperglycemia.
In March 2019, the patient presented at our clinic for further treatment owing to tumor progression. We promptly initiated a treatment regimen comprising a combina- tion of octreotide (sandostatin LAR) and CAPTEM (capecitabine and temozolo- mide). However, during the course of this treatment, he developed psychiatric symp- toms, including auditory hallucination,
manic episodes, and delusional episodes. Laboratory testing revealed a low blood potassium concentration of 2.4 mmol/L (normal range 3.5 to 5.5 mmol/L), high plasma ACTH concentrations of 51.6 pmol/ L at 08:00 and 50.2 pmol/L at 00:00 (normal range 1.59 to 13.96 pmol/L), a high serum cortisol concentration of 1,750 nmol/L at
08:00 (normal range 118 to 868 nmol/L), and an absence of normal diurnal variation. His 24-hour urinary free cortisol production was also significantly higher than normal (Table 1). Abdominal enhanced computed tomography (CT) examination revealed hepatic tumors with irregular enhancement and bilateral hyperplasia of the adrenal
| Normal range | Case 1 | Case 2 | Case 3 | |
|---|---|---|---|---|
| Sex | Male | Male | Female | |
| Clinical symptoms | auditory hallucination, mania, suspicion, insensitivity, communi- cation disorders, uri- nary incontinence, insomnia | facial and extremity edema, auditory hallu- cination, hyperactivity, insomnia | lassitude, insomnia | |
| Plasma ACTH (pmol/L) | ||||
| At 00:00 | 1.59-13.96 | 50.19 | NA | 80.42 |
| At 08:00 | 1.59-13.96 | 51.62 | 61.72 | 93.20 |
| Serum cortisol (nmol/L) | ||||
| At 00:00 | 0-185 | >1,750 | NA | >1,655 |
| At 08:00 | 118-686 | >1,750 | 1,039 | >1,655 |
| 24-hour urine cortisol (ug/day) | >1,750 | NA | >1,655 | |
| 24-hour UFC (µg/day) | >2,030.08 | NA | NA | |
| Blood pressure (mmHg) | ||||
| Systolic | 90-140 | 166 | 170 | 200 |
| Diastolic | 60-90 | 112 | 80 | 104 |
| Potassium (mmol/L) | 3.5-5.5 | 2.40 | 3.00 | 2.10 |
| Blood glucose (mmol/L) | 3.61-6.11 | 10.16 | 23.3 | 7.31 |
| Pancreatic tumor size (cm) | 5.1 × 4.6 | 6.3 × 5.7 | 2.4 × 1.3 | |
| Location | Tail | Tail | Neck | |
| Surgery | Yes | No | Yes | |
| Grade | NET G2 | NET G2 | NET G2 | |
| Ki-67 | 3% | 4% | 5% | |
| Type of surgery | Debulking surgery | NA | Radical mastectomy | |
| Metastases | Liver, inguinal lymph nodes | Liver, spleen, kidney, retroperitoneal lymph nodes, bone | Liver, retroperitoneal lymph nodes | |
| AJCC staging | IV | IV | IV | |
| T | T4 | T4 | T2 | |
| N | N1 | N1 | N1 | |
| M | M1c | M1c | M1c | |
| Outcome | Death | Death | Death | |
| Duration of follow-up | 66 | 11.5 | 44.6 | |
| (months) |
ACTH, adrenocorticotropic hormone; UFC, urinary free cortisol; NA, not available, AJCC, American Joint Committee on Cancer
glands. Magnetic resonance imaging (MRI) of his pituitary showed no abnormalities (Figure 2a, 2d, 2g).
On the basis of the patient’s medical his- tory, symptoms, laboratory data, and imag- ing findings, an initial diagnosis of EAS caused by advanced p-NET was made. We subsequently proposed bilateral inferior petrosal sinus sampling to confirm the diag- nosis; however, the patient declined this procedure. After a single cycle of anti-tumor treatment, the hepatic tumors exhibited sig- nificant shrinkage, and the patient’s serum ACTH and cortisol concentrations returned to normal without the necessity for any treat- ment for Cushing’s syndrome. The features of EAS also improved. As the tumors continued to decrease in size, the patient’s hormone con- centrations and the clinical manifestations of the disease improved, providing support for the diagnosis.
Subsequently, we continued the anti- tumor therapy, which alleviated his EAS symptoms. However, his tumor started to progress again in December 2021, resulting
in increases in his circulating ACTH and cortisol concentrations and a worsening of his symptoms. Therefore, we introduced a new treatment regimen for the tumor, and to manage the hypercortisolemia, we intro- duced mitotane at a dose of 1,000 mg three times daily. After approximately 7 days of treatment, the patient’s serum cortisol concentration had returned to normal (Figure 1), and he had not experienced any significant adverse effects. During the follow-up period, the patient’s hypercorti- solemia remained under control using a maintenance dose of mitotane (serum corti- sol concentration at 08:00 between 275 and 668 nmol/L), despite tumor progression. Unfortunately, the patient eventually died owing to complications of the malignancy, after surviving 66 months.
Case 2
A man of approximately 60 years of age was admitted to his local hospital in September 2021 with fatigue and facial and limb edema. Subsequent investigations
1800
Serum cortisol at 08:00 AM(nmol/L)
1600
1400
1200
1000
800
600
400
200
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
Day of hospitalization
case 1
case 2
case 3
case 1
case 2
case 3
Liver metastases
(a)
(b)
(c)
Adrenal gland
(d)
(e)
(f)
Pituitary gland
(g)
(h)
(i)
revealed the presence of a grade 2 (G2) pan- creatic neuroendocrine tumor (p-NET) with multiple metastases, including in the liver, retroperitoneal lymph nodes, and bones. Following three cycles of CAPTEM chemo- therapy that were not curative, the patient sought further treatment at our clinic in December 2021. During his hospitalization, he exhibited symptoms of hyperactivity, sub- stantial appetite, and impaired sleep.
Physical examination revealed hyperten- sion (170/80 mmHg), facial plethora, and edema of the face and limbs. However, moon face, buffalo hump, central obesity, and purple striae were absent. Laboratory
testing revealed a serum potassium concen- tration of 3.0 mmol/L, a fasting blood glucose concentration of 23.3 mmol/L, and high plasma ACTH and serum cortisol con- centrations (Table 1). Subsequently, a series of imaging examinations were performed. An abdominal enhanced CT examination revealed hepatomegaly, adrenal hyperpla- sia, diffuse tumors with annular enhance- ment in the liver, and a well-defined mass measuring 6.3 cm × 5.7cm with regular enhancement in the tail of the pancreas, which invaded the patient’s left kidney and spleen. However, pituitary enhanced MRI did not reveal any abnormalities
(Figure 2b, 2e, 2h). On the basis of these findings, we suspected that the neuroendo- crine tumor might be an ectopic ACTH- secreting neoplasm.
Treatment of the tumor was initiated immediately after assessing the patient’s condition using octreotide and surufatinib. In addition, mitotane administration was commenced to manage his hypercortisole- mia, initially at a dose of 1,000 mg three times daily, and the patient’s serum cortisol concentration returned to normal after 6 days of this medication. Furthermore, his clinical symptoms improved. To prevent adrenal insufficiency, the patient’s circulat- ing hormone concentrations were moni- tored over an extended period. Ultimately, his serum cortisol concentration remained within the normal range while administer- ing the minimum dose of mitotane (1,000 mg/day), with occasional adjust- ments of the dose owing to fluctuations in hormone concentrations.
Owing to the patient’s substantial tumor burden and the high activity of the neo- plasms, his plasma ACTH concentration increased to 225 pmol/L in March 2022. However, mitotane treatment was associat- ed with stability of his serum cortisol con- centration (at 08:00, ranging from 122 to 716 nmol/L) and the clinical manifestations of the disease. In addition, he experienced no significant adverse effects, with only slight loss of appetite and dizziness. Unfortunately, the patient ultimately died owing to the effects of the tumor, resulting in a duration of survival of 11.5 months.
Case 3
A woman of approximately 60 years of age underwent surgical resection of a pancreatic neck tumor in September 2019. The tumor measured approximately 2.4 × 1.3 cm, and microscopic and immunohistochemical analysis showed that it was a grade 2 (G2) p-NET with a Ki-67 index of 5%.
No adjuvant therapy was administered fol- lowing the surgery, and 2 years later, an abdominal MRI examination revealed the presence of multiple liver masses, with the largest measuring 2.1 cm, and multiple retro- peritoneal lymph node masses. Subsequently, the patient underwent CAPTEM chemother- apy at our clinic. After completing three cycles of treatment in January 2022, she returned to the hospital for an evaluation of the treatment’s effectiveness. During the assessment, she complained of weakness in her lower limbs, which significantly affected her ability to walk steadily.
During the physical examination, the patient’s lower limb muscle strength was found to be poor, and she had hypertension (200/104 mmHg). Laboratory testing revealed severe hypokalemia (2.1 mmol/L), hyperglycemia (fasting blood glucose con- centration of 7.31 mmol/L), high circulating ACTH and cortisol concentrations, with a lack of diurnal variation, and 24-hour urine cortisol production of >60 µg/day. However, she showed no classic signs of Cushing’s syndrome. Therefore, the patient underwent additional imaging examinations and liver biopsy. Abdominal enhanced MRI revealed the progression of the metastases in the liver and retroperitoneal lymph nodes, with the largest tumor measuring approxi- mately 2.6 x 2.1 cm. Bilateral adrenal hyper- plasia was also observed. Pituitary enhanced MRI did not indicate any abnormalities (Figure 2c, 2f, 2i). Examination of the liver biopsy revealed a grade 3 (G3) neuroendo- crine tumor with a Ki-67 index of 22% and positive immunostaining for ACTH (Figure 3), implying the presence of EAS.
In addition to symptomatic and anti- tumor therapy, mitotane (1,000mg three times daily) was administered to manage the patient’s hypercortisolemia. After 14 days of treatment, her cortisol concentration had returned to normal (Figure 1); and her serum potassium, blood pressure, and blood sugar were under control; without any adverse
(a)
(b)
(c)
Đ
(d)
(e)
(f)
events being recorded. Subsequently, the min- imum necessary dose of mitotane for mainte- nance was determined through regular monitoring of the patient’s circulating cortisol concentration. Until the patient died on May 14, 2023, her hypercortisolemia remained under control through the use of mitotane (serum cortisol concentrations at 08:00 between 390 and 530 nmol/L). The patient sur- vived for 44.6 months.
Discussion
The findings of the present case series sug- gest that mitotane alone can be used to con- trol hypercortisolemia resulting from ectopic ACTH production in patients with p-NETs. This treatment showed promising results with respect to the symptoms and survival of the patients.
In the majority of patients, EAS is typi- cally diagnosed synchronously, within
a period of approximately 3 months before or after an initial diagnosis of a malignant tumor, whereas metachronous EAS, which is diagnosed more than 3 months after the initial diagnosis of a tumor, is relatively uncommon. However, some patients are diagnosed with EAS dec- ades after Cushing’s syndrome is identified, when small tumors are found.7-9 It is note- worthy that patients with EAS do not always exhibit the clinical characteristics of Cushing’s syndrome. However, sudden severe hypokalemia is a key clinical feature of EAS, which is observed in approximately 42% to 86% of patients, and is a valuable diagnostic criterion. In the present study, two of the patients had synchronous EAS and one had metachronous EAS. All of them presented with advanced tumors, a substantial tumor burden, and severe hypo- kalemia. When diagnoses of p-NET-related EAS are made, the majority of patients
have already developed distant metastases, with liver metastases being particularly common.1º One possible explanation for this is that the ACTH secreted by pancreat- ic neoplasms is rapidly degraded in the liver after arriving via the enterohepatic circula- tion, and clinical symptoms only manifest when the tumors produce a sufficient quantity of hormone.11 Another possible explanation is the heterogeneity of neuroen- docrine tumors, the histopathological or endocrine properties of which can change when they metastasize, resulting in the tumor becoming the principal source of ACTH. This has been documented in sev-
lating ACTH concentrations cause hypercortisolemia, which has a significant detrimental effect on the prognosis of patients and can be life-threatening. A pre- vious systematic review of 336 patients with p-NET-related EAS that recorded the prog- nosis of 164 of these patients only followed them for 28.3 months (range 1 month to 20 years).10 However, in this situation, the pharmaceutical control of hypercortisolism is mandatory.
Adrenal inhibitors of steroidogenesis, such as metyrapone, ketoconazole, etomi- date, osilodrostat, and mitotane, are recom- mended by the Endocrine Society Clinical Practice Guidelines as first-line treatments for patients with metastatic EAS.14 Of these, mitotane appears to be the most suit- able option, on the basis of the present assessment. Ketoconazole use can be asso- ciated with hepatotoxicity, which poses a risk for patients with liver metastases;15 metyrapone may mask biochemical hypoa- drenalism and can occasionally cause hypertension, edema, and hypokalemia;14 and etomidate requires continuous infusion and close monitoring, which is difficult to achieve.16 A previous case report showed that abiraterone acetate can also signifi- cantly reduce cortisol concentrations,17 but it can also aggravate the hypertension
and hypokalemia of patients. Furthermore, it is unclear whether this drug can maintain cortisol concentrations of patients with unresectable advanced tumors within the normal range.
Mitotane is an analog of the insecticide dichlorodiphenyltrichloroethane and is the only medication approved by the United States Food and Drug Administration and the European Medicines Agency for the treatment of adrenocortical carcinoma. It has a direct cytotoxic effect on the adre- nal cortex through free radical-mediated metabolic transformation and oxidative damage, and inhibits adrenocortical steroid synthesis by inhibiting cholesterol side- chain cleavage and 11ß-hydroxylase.19 Mitotane also affects extra-adrenal cortisol bioavailability by increasing its hepatic clearance and the secretion of cortisol- binding protein, thereby reducing the avail- ability of the hormone.20 This complex mechanism of action makes it an effective treatment for hypercortisolemia,21 and ren- ders it a viable option for the management of hypercortisolism in such patients.
In a review by Donadille et al., data for 23 patients who underwent mitotane treat- ment at the Department of Endocrinology, Cochin Hospital were analyzed. Of these patients, four who had small-cell lung cancer did not undergo surgery and were followed for a median 1.025 years; 14 under- went surgical treatment and were followed for a median 11.66 years; and five individ- uals were found not to have tumors and were followed for a median 4.24 years. Only nine of these patients received mito- tane as a single anti-cortisol medication.22 Thus, there is currently limited experience with the use of mitotane as a standalone treatment for patients with advanced tumor-related EAS, and the available data do not conclusively demonstrate the bene- fits of this treatment for patients.
In the present study, three patients with advanced p-NET were diagnosed with EAS
on the basis of a comprehensive assessment of their medical history, laboratory data, imaging findings, and response to anti- tumor therapy. Their excessive secretion of ACTH, resulting in adrenal gland hypertro- phy and consequent hypercortisolism, was attributed to liver metastases that could not be completely eradicated. To treat this con- dition, in addition to administering anti- tumor therapy, we administered 3,000 mg/ day mitotane to reduce the plasma cortisol concentrations of the patients and induce the destruction of their adrenal glands. Subsequently, we closely monitored the patients’ circulating hormone concentra- tions and those of other biochemical indices until they returned to normal, which hap- pened after a mean of 9 days. Following long-term monitoring and extensive deliber- ation by our team, we gradually reduced the dose of mitotane to the minimum necessary to maintain the suppression of the patients’ hypercortisolism. Unfortunately, all three of the patients ultimately died because of tumor progression, but the median duration of follow-up was 39.6 months. It is worth noting that despite the ultimately negative outcomes, mitotane therapy was effective at maintaining the patients’ circulating corti- sol concentrations within the normal range, despite tumor progression, and the duration of survival of the present patients was longer than that previously reported for patients with inoperable EAS.
The present study had a few limitations that should be addressed. First, the diag- nostic process used could have been further strengthened to enhance the accuracy and reliability of the diagnoses made. Second, we did not measure the circulating concentrations of mitotane during the treat- ment period. Monitoring these concentra- tions could provide valuable information regarding the therapeutic efficacy of the drug and help optimize the dose administered.
Conclusions
This case series suggests that in situations where surgical intervention is not feasible, mitotane represents an effective and rapid means of controlling the life-threatening hypercortisolism associated with advanced p-NET. When used in combination with anti-tumor therapy, mitotane is well tolerat- ed and has the potential to extend the sur- vival of patients. However, further clinical trials are necessary to validate the effective- ness of mitotane treatment in such patients. Continued research in this area should pro- vide valuable insights and contribute to the identification of the optimal treatment strat- egies for patients with advanced p-NET and ectopic ACTH syndrome.
Acknowledgements
We thank the patients and their families for sup- porting the treatment of the patients.
Author contributions
SH performed the data analyses and wrote the manuscript; XW contributed to the manuscript preparation and the collection of clinical data; FS performed the review and revision of the manuscript; QZ contributed to the production of the figures and tables; ZL contributed to the analysis with constructive discussions; JL pro- vided the pathological diagnosis and pictures; and HT contributed to the conception of the study and the analysis by constructive discussions.
Declaration of conflicting interests
The authors declare that there is no conflict of interest.
Ethics statement
We obtained approval from the China-Japan Friendship Hospital ethics committee for the publication of this article. Because it was a ret- rospective study, the requirement for ethics approval was waived. All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national
research committee(s) and with the Helsinki Declaration (as revised in 2013). The authors are accountable for all aspects of the work, and will ensure that questions related to the accuracy or integrity of any part of the work are appro- priately investigated and resolved. Written informed consent was obtained from the rela- tives of the patients for publication of this case series and the accompanying images.
Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
ORCID İD
Huangying Tan [D https://orcid.org/0000-0002- 6165-5196
References
1. Lacroix A, Feelders RA, Stratakis CA, et al. Cushing’s syndrome. Lancet (London, England) 2015; 386: 913-927. DOI: 10.1016/S0140-6736(14)61375-1
2. Young J, Haissaguerre M, Viera-Pinto O, et al. Management of endocrine disease: Cushing’s syndrome due to ectopic ACTH secretion: an expert operational opinion. Eur J Endocrinol 2020; 182: R29-R58. DOI: 10.1530/EJE-19-0877
3. Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non- functional pancreatic neuroendocrine tumors. Neuroendocrinology 2016; 103: 153-171. DOI: 10.1159/000443171
4. Pivonello R, Isidori AM, De Martino MC, et al. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol 2016; 4: 611-629. DOI: 10.1016/S2213-8587 (16)00086-3
5. Zhang C, Jin J, Xie J, et al. The clinical features and molecular mechanisms of ACTH-secreting pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 2020; 105: dgaa507. DOI: 10.1210/clinem/dgaa507
6. Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical
case reporting guideline development. Headache 2013; 53: 1541-1547. DOI: 10.1111/head.12246
7. Kamp K, Alwani RA, Korpershoek E, et al. Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroen- teropancreatic and thoracic neuroendocrine tumors. Eur J Endocrinol 2016; 174: 271-280. DOI: 10.1530/EJE-15-0968
8. Najafipour F, Bahrami A, Niafar M, et al. Median 10 years follow-up of patients with covert Cushing’s syndrome: a case series. J Med Case Rep 2021; 15: 514. DOI: 10.1186/s13256-021-03046-3
9. Toivanen S, Leijon H, Arola A, et al. Characteristics and outcomes of the Finnish ectopic ACTH syndrome cohort. Endocrine 2021; 74: 387-395. DOI: 10.1007/s12020-021-02768-0
10. Wu Y, Xiong G, Zhang H, et al. Adrenocorticotropic hormone-producing pancreatic neuroendocrine neoplasms: a sys- tematic review. Endocr Pract 2021; 27: 152-157. DOI: 10.1016/j.eprac.2020.10.012
11. Yao WQ, Wu X, Li GD, et al. ACTH- secreting pancreatic neuroendocrine carcino- ma with ovarian and pelvic metastases causing Cushing’s syndrome: a case report. Int J Clin Exp Pathol 2015; 8: 15396-15401.
12. Maragliano R, Vanoli A, Albarello L, et al. ACTH-secreting pancreatic neoplasms asso- ciated with Cushing syndrome: clinicopath- ologic study of 11 cases and review of the literature. Am J Surg Pathol 2015; 39: 374-382. DOI: 10.1097/PAS.0000000000 000340
13. Kondo T, Matsuyama R, Ashihara H, et al. A case of ectopic adrenocorticotropic hormone-producing pancreatic neuroendo- crine tumor with multiple liver metastases. Endocr J 2010; 57: 229-236. DOI: 10.1507/ endocrj.k09e-179
14. Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100: 2807-2831. DOI: 10.1210/jc.2015-1818
15. Young J, Bertherat J, Vantyghem MC, et al. Hepatic safety of ketoconazole in Cushing’s syndrome: results of a compassionate use programme in France. Eur J Endocrinol
2018; 178: 447-458. DOI: 10.1530/eje-17- 0886
16. Carroll TB, Peppard WJ, Herrmann DJ, et al. Continuous etomidate infusion for the management of severe Cushing syn- drome: validation of a standard protocol. J Endocr Soc 2019; 3: 1-12. DOI: 10.1210/ js.2018-00269
17. Chacko R, Abdel-Razeq NH, Abu Rous F, et al. Abiraterone acetate for treatment of ectopic Cushing syndrome caused by ACTH-producing neuroendocrine tumor: a case report. J Gastrointest Oncol 2022; 13: 2626-2632. DOI: 10.21037/jgo-22-376
18. Puglisi S, Calabrese A, Basile V, et al. New perspectives for mitotane treatment of adre- nocortical carcinoma. Best Pract Res Clin Endocrinol Metab 2020; 34: 101415. DOI: 10.1016/j.beem.2020.101415
19. Veytsman I, Nieman L and Fojo T. Management of endocrine manifestations
and the use of mitotane as a chemotherapeu- tic agent for adrenocortical carcinoma. J Clin Oncol 2009; 27: 4619-4629. DOI: 10.1200/jco.2008.17.2775
20. Young RB, Bryson MJ, Sweat ML, et al. Complexing of DDT and o,p’DDD with adrenal cytochrome P-450 hydroxylating sys- tems. J Steroid Biochem 1973; 4: 585-591. DOI: 10.1016/0022-4731(73)90033-2
21. Ciato D, Mumbach AG, Paez-Pereda M, et al. Currently used and investigational drugs for Cushing’s disease. Expert Opin Investig Drugs 2017; 26: 75-84. DOI: 10.1080/13543784.2017.1266338
22. Donadille B, Groussin L, Waintrop C, et al. Management of Cushing’s syndrome due to ectopic adrenocorticotropin secretion with 1, ortho-1, para’-dichloro-diphenyl-dichloro- ethane: findings in 23 patients from a single center. J Clin Endocrinol Metab 2010; 95: 537-544. DOI: 10.1210/jc.2009-1317